logo

A study on indirect radiolabeling of IgG with carrier free 188Re

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

A study on indirect radiolabeling of IgG with carrier free 188Re

ZHANG Xiu-Li
WANG Yong-Xian
LI Jun-Ling
YIN Duan-Zhi
Nuclear Science and TechniquesVol.14, No.2pp.131-134Published in print 01 May 2003
21900

188Re labeled monoclonal antibodies are potential candidates for use in radioimmunotherapy. S-Bz-MAG3 as a bifunctional chelating agent was used for labeling of IgG with carrier free 188Re by pre-radiolabeling of the chelating approach. The conjugation conditions were optimized. The stability of 188Re-MAG3-IgG in vitro was high. The results may be useful to the studies of 188Re labeled MAbs for radioimmunotherapy.

Carrier free 188ReIgGS-Bz-MAG3RadioimmunotherapyBifunctional chelating agentIndirect radiolabeling
References
[1] Sykes T R, Somayaji V V, Bier S et al. Appl Radiat Isot, 1997, 48: 899-906
[2] Griffiths G L, Goldenberg D M, Knapp F F et al. Cancer Res, 1991, 51: 4594-4602
[3] Iznago-Escobar N. Nucl Med Biol, 1998, 25: 441-447
[4] Yu J F, Yin D Z, Min X F et al. J Labelled Cpd Radiopham, 1999, 42: 233-243
[5] Ding Z G, Yu J F, Yin D Z et al. Nucl Tech (in Chinese), 2000, 23: 762-766
[6] Najafi A, Alauddin M M, Sosa A et al. Nucl Med Biol, 1992, 19: 205-212
[7] Guhlke S, Schaffland A, Zamora P O et al. Nucl Med Biol, 1998, 25: 621-631
[8] Visser G W M, Gerretsen M, Herscheid J D M et al. J Nucl Med,1993, 34: 1953-1963
[9] Gog F B, Visser G W M, Klok R et al. J Nucl Med, 1996, 37: 352-362
[10] Hjelstuen O K, Tφnnesen H H, Bremer P O et al. Nucl Med Biol, 1998, 25: 651-657
[11] Gog F B, Visser G W M, Gowrising R W A et al. Nucl Med Biol, 1998, 25: 611-619
[12] Fritzberg A R, Kasina S, Eshima D et al. J Nucl Med, 1986, 27: 111-116